AR037131A1 - Formulaciones de jarabe de ribavirina - Google Patents

Formulaciones de jarabe de ribavirina

Info

Publication number
AR037131A1
AR037131A1 ARP020104108A ARP020104108A AR037131A1 AR 037131 A1 AR037131 A1 AR 037131A1 AR P020104108 A ARP020104108 A AR P020104108A AR P020104108 A ARP020104108 A AR P020104108A AR 037131 A1 AR037131 A1 AR 037131A1
Authority
AR
Argentina
Prior art keywords
ribavirina
syrup formulations
ribavirin
pharmaceutically acceptable
liquid formulation
Prior art date
Application number
ARP020104108A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR037131A1 publication Critical patent/AR037131A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulación líquida que comprende ribavirina que tiene una vida de estantería más larga y sabor mejorado. Reivindicación 1: Una fórmula líquida que comprende ribavirina; un sistema de tamponamiento, encontrándose el pH de la formulación líquida en el orden de desde aproximadamente 4,8 a aproximadamente 5,3; por lo menos un agente edulcorante farmacéuticamente aceptable; y por lo menos un agente que incrementa la viscosidad farmacéuticamente aceptable
ARP020104108A 2001-10-31 2002-10-29 Formulaciones de jarabe de ribavirina AR037131A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33475101P 2001-10-31 2001-10-31

Publications (1)

Publication Number Publication Date
AR037131A1 true AR037131A1 (es) 2004-10-20

Family

ID=23308655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104108A AR037131A1 (es) 2001-10-31 2002-10-29 Formulaciones de jarabe de ribavirina

Country Status (27)

Country Link
US (1) US6790837B2 (es)
EP (1) EP1480653B1 (es)
JP (1) JP4393192B2 (es)
KR (1) KR100929320B1 (es)
CN (1) CN1319535C (es)
AR (1) AR037131A1 (es)
AT (1) ATE439847T1 (es)
AU (1) AU2002350081B2 (es)
BR (1) BR0213536A (es)
CA (1) CA2464151C (es)
CO (1) CO5570681A2 (es)
CY (1) CY1110524T1 (es)
DE (1) DE60233438D1 (es)
DK (1) DK1480653T3 (es)
ES (1) ES2330419T3 (es)
HK (1) HK1066719A1 (es)
HU (1) HU229259B1 (es)
MX (1) MXPA04004068A (es)
NO (1) NO334361B1 (es)
NZ (1) NZ531967A (es)
PE (1) PE20030545A1 (es)
PL (1) PL205342B1 (es)
PT (1) PT1480653E (es)
SI (1) SI1480653T1 (es)
TW (1) TWI259082B (es)
WO (1) WO2003037312A2 (es)
ZA (1) ZA200402975B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2540052C (en) * 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
US20060110479A1 (en) * 2004-11-24 2006-05-25 Mitra Shankar K Natural composition for curing hepatitis-B, methods for making the same and pharmaceutical formulations thereof
BRPI0815562A2 (pt) * 2007-07-12 2015-02-18 Novartis Ag Soluções farmacêuticas orais contendo telbivudina.
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013149258A2 (en) 2012-03-30 2013-10-03 Charles Drew University of Medicine and Science Compositions and methods for treating or preventing metabolic syndrome disorders
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190336443A1 (en) * 2018-05-03 2019-11-07 Navinta Iii Inc Ready-To-Use Liquid Parenteral Formulations Of Ribavirin
CN109568257A (zh) * 2018-12-24 2019-04-05 江西润泽药业有限公司 一种利巴韦林注射液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
JPS58198416A (ja) * 1982-05-15 1983-11-18 Ota Seiyaku Kk セフアレキシンドライシロツプ剤の製造法
JPS63177797A (ja) * 1987-01-19 1988-07-21 Ajinomoto Co Inc リボ−ス−１−リン酸及びリバビリンの製造法
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
DE69531611T2 (de) * 1994-04-28 2004-02-26 Bionumerik Pharmaceuticals, Inc., San Antonio Lactone-stabile camptothecin oder 7 - ethyl camptothecin - formulierung in dimethylisosorbid oder dimethylacetamid
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6132758A (en) * 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup

Also Published As

Publication number Publication date
HUP0600300A2 (en) 2006-07-28
PL372224A1 (en) 2005-07-11
HK1066719A1 (en) 2005-04-01
CO5570681A2 (es) 2005-10-31
NO334361B1 (no) 2014-02-17
ES2330419T3 (es) 2009-12-10
MXPA04004068A (es) 2004-09-06
KR100929320B1 (ko) 2009-11-27
DE60233438D1 (de) 2009-10-01
CA2464151A1 (en) 2003-05-08
PE20030545A1 (es) 2003-06-19
NO20042228L (no) 2004-05-28
CY1110524T1 (el) 2015-04-29
US20030087844A1 (en) 2003-05-08
EP1480653A2 (en) 2004-12-01
JP4393192B2 (ja) 2010-01-06
CA2464151C (en) 2010-09-14
ATE439847T1 (de) 2009-09-15
AU2002350081B2 (en) 2005-09-22
JP2005507931A (ja) 2005-03-24
TW200300343A (en) 2003-06-01
BR0213536A (pt) 2004-10-19
DK1480653T3 (da) 2009-11-30
CN1319535C (zh) 2007-06-06
KR20040047938A (ko) 2004-06-05
US6790837B2 (en) 2004-09-14
CN1582155A (zh) 2005-02-16
EP1480653B1 (en) 2009-08-19
WO2003037312A2 (en) 2003-05-08
ZA200402975B (en) 2005-06-29
PL205342B1 (pl) 2010-04-30
HU229259B1 (en) 2013-10-28
WO2003037312A3 (en) 2004-09-23
TWI259082B (en) 2006-08-01
NZ531967A (en) 2005-10-28
SI1480653T1 (sl) 2009-12-31
PT1480653E (pt) 2009-10-20

Similar Documents

Publication Publication Date Title
DE69910230D1 (de) Paclitaxel enthaltende arzneimittel
HRP20060240T3 (en) Intranasal formulation of rotigotine
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
AR037131A1 (es) Formulaciones de jarabe de ribavirina
EP2263651A3 (en) Low viscosity liquid dosage forms
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
CU23536A3 (es) Estabilizador de interleuquina 2
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
CO5231147A1 (es) Composicion congelante
RS49764B (sr) Farmaceutski preparat za primenu na mukozu
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
ATE333290T1 (de) Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
AP2003002907A0 (en) Liquid pharmaceutical composition.
PE20021017A1 (es) Composicion parenteral reconstituible
BRPI0407583A (pt) solução oftálmica lìmpida e estável
MXPA02010648A (es) Formulaciones liquidas.
DE69912262D1 (de) Retinolhaltiges arzneimittel kompatibel mit weichgelatinekapseln
NZ560648A (en) Formulation for aviptadil (vasoactive intestinal peptide, VIP)
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
ATE388960T1 (de) Glykopeptidderivate mit carboxysacchariden
BR0005332A (pt) Aroma encapsulado

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration